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Abstract
NF-κB signaling plays a critical role in tumor growth and treatment resistance in GBM as in many other cancers. However,
the molecular mechanisms underlying high, constitutive NF-κB activity in GBM remains to be elucidated. Here, we screened
a panel of tripartite motif (TRIM) family proteins and identified TRIM22 as a potential activator of NF-κB using an NF-κB
driven luciferase reporter construct in GBM cell lines. Knockout of TRIM22 using Cas9-sgRNAs led to reduced GBM cell
proliferation, while TRIM22 overexpression enhanced proliferation of cell populations, in vitro and in an orthotopic xenograft
model. However, two TRIM22 mutants, one with a critical RING-finger domain deletion and the other with amino acid
changes at two active sites of RING E3 ligase (C15/18A), were both unable to promote GBM cell proliferation over controls,
thus implicating E3 ligase activity in the growth-promoting properties of TRIM22. Co-immunoprecipitations demonstrated
that TRIM22 bound a negative regulator of NF-κB, NF-κB inhibitor alpha (IκBα), and accelerated its degradation by inducing
K48-linked ubiquitination. TRIM22 also formed a complex with the NF-κB upstream regulator IKKγ and promoted K63-
linked ubiquitination, which led to the phosphorylation of both IKKα/β and IκBα. Expression of a non-phosphorylation
mutant, srIκBα, inhibited the growth-promoting properties of TRIM22 in GBM cell lines. Finally, TRIM22 was increased in a
cohort of primary GBM samples on a tissue microarray, and high expression of TRIM22 correlated with other clinical
parameters associated with progressive gliomas, such as wild-type IDH1 status. In summary, our study revealed that TRIM22
activated NF-κB signaling through posttranslational modification of two critical regulators of NF-κB signaling in GBM cells.
Introduction
The NF-κB pathway, originally characterized within the
context of the immune system, has been implicated in many
hallmarks of cancer development, including cellular pro-
liferation, angiogenesis, and resistance to therapy [1–3]. As
in other malignancies, high, constitutive NF-κB activity has
been observed in human glioblastoma (GBM). It has been
found to promote mesenchymal differentiation and therapy
resistance in the disease [4], and also plays a central role in
many other active oncogenic pathways in GBM [5–10].
Expression profiling and molecular analysis has demon-
strated that GBMs with mesenchymal features exhibit ele-
vated levels of NF-κB pathway genes, such as RELB and
TRADD [11]. However, mutation or amplification of NF-κB
signaling subunits is rare in tumors, suggesting that aberrant
activation of NF-κB signaling in GBM may be attributed to
deregulation of the pathway or oncogenes.
Ubiquitination, one of the most common and important
types of posttranslational modification, has been implicated
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in many diseases including cancers [12, 13]. The most well-
studied polyubiquitin chain types include lysine 48 (K48)
and lysine 63 (K63) linkages. K48-linked polyubiquitin
chains predominantly target proteins for degradation, while
K63 chains regulate kinase activity, signal transduction, and
endocytosis [14, 15]. Over the past decade, posttranslational
modification, especially ubiquitin (Ub) modification, has
emerged as a crucial participant in NF-κB activation [16].
Following stimulation, signaling intermediaries, such as
TNF receptor-associated factors and receptor interacting
protein, are rapidly modified with K63-linked poly-Ub
chains, leading to activation of downstream kinases, such as
TGF-β-activated kinase 1 and IKK complexes that partici-
pate in NF-κB signaling. The IKK complex is made up of
two catalytic subunits (IKKα and IKKβ) and a noncatalytic
regulatory subunit (IKKγ) [16–20]. Transcriptional activa-
tion of NF-κB occurs when the IKK complex becomes
activated and phosphorylates IκB proteins. Phosphorylation
of IκBα frees NF-κB, which is translocated to the nucleus,
while phosphorylated IκBα is targeted for degradation after
modification with K48-linked Ub chains [21].
One subfamily of the RING type E3 Ub ligases, the
tripartite motif (TRIM) proteins, is emerging as a key reg-
ulator in the development of diverse cancers by modulating
transcriptional activity of NF-κB, including GBM [13].
TRIM40 was reported to physically binds to NEDD8 and
promotes the neddylation of IKKγ to inhibit NF-κB acti-
vation in gastrointestinal carcinomas [22]. TRIM24 has also
been shown to significantly alter transcriptional activity of
NF-κB in EGFRvIII-driven GBM cells [23]. Here, using
NF-κB response reporters and public databases, we further
investigated the role of TRIM proteins in the development
of GBM. We screened a panel of TRIM proteins using an
NF-κB driven luciferase reporter construct and identified
TRIM22 as an activator of NF-κB signaling in GBM cells.
TRIM22, rarely investigated in most human cancers, reg-
ulates biological processes in various cell types through NF-
κB signaling, including macrophages [24, 25], neurons [26],
and human embryonic kidney 293 T cells (HEK293T)
[27, 28]. We found it not only promoted K48-linked ubi-
quitination of IκBα by directly associating with it, but also
enhanced K63-linked ubiquitination of IKKγ. Thus,
TRIM22 both activates the IKK complex and promotes
degradation of IκBα, thereby leading to high transcriptional
activity of NF-κB in GBM cells.
Materials and methods
Ethics statement
All primary glioma tissue samples (n= 112) and matching
clinical data were obtained from the Department of
Neurosurgery at Qilu Hospital of Shandong University [29].
Nonneoplastic brain tissue samples (NBT; n= 10) were
obtained from the Department of Pathology at Qilu Hospital of
Shandong University. All experiments and the use of human
tissues were approved by the Research Ethics Committee of
Shandong University and the Ethics Committee of Qilu Hos-
pital in accordance with the Declaration of Helsinki (for
humans) and the U.S. Public Health Service Policy on Human
Care and Use of Laboratory Animals (2015 reprint; for mice).
Written informed consent was obtained from all adult patients.
Cell culture
Human GBM cell lines (U87MG, U118MG and LN229) and
the human embryonic kidney cell line 293 (HEK293) were
purchased from the American Type Culture Collection. All
human cell lines were authenticated and submitted for short
tandem repeat analysis (Cell Cook Biotech Co. LTD;
Guangzhou, China). Primary GBM#P3 cells and BG5 glioma
stem cells (GSC) were kind gifts provided by Prof. Rolf
Bjerkvig (University of Bergen, Norway). Cells (U87MG,
U118MG, LN229, and HEK293) were maintained in the
Dulbecco’s modified Eagle’s medium (DMEM; Life Tech-
nologies/Thermo Fisher Scientific; Waltham, MA, USA)
supplemented with 10% fetal bovine serum (Thermo Fisher
Scientific). Cells (GBM#P3 and GSC BG5) were cultured in
serum-free DMEM/F12 medium (Gibco/Thermo Fisher Sci-
entific) supplemented with 2% B27 Neuro Mix (Thermo
Fisher Scientific), epidermal growth factor (20 ng/mL;
Thermo Fisher Scientific), and basic fibroblast growth factor
(10 ng/mL; Thermo Fisher Scientific). Cells were maintained
at 37 °C in a humidified chamber containing 5% CO2.
Transient transfection, lentiviral infection, and Cas9-
sgRNA knockout
Transient transfections for siRNAs and plasmids were per-
formed with Lipofectamine 2000 or 3000 (Thermo Fisher
Scientific) as we previously described [30]. The sequences
of siRNAs used are listed in Supplementary Table S1, and
plasmids used are listed in Supplementary Table S2.
The Puro-3×Flag-hCas9 and single-guide RNA
(sgRNAs) lentiviruses were designed and constructed by
OBiO Technology Company (Shanghai, China). Lentivirus
containing Cas9 and sgRNAs (sg-scramble, sg-TRIM22-1
or sg-TRIM22-2) were introduced into U87MG, LN229,
GBM#P3, and BG5 cells. The sequences of sgRNAs used
are listed in Supplementary Table S1.
In addition, lentiviral constructs for ectopic expression of
full-length TRIM22 (Flag-TRIM22-FL; OBiO Technology),
a RING-finger domain deletion mutant of TRIM22 (Flag-
TRIM22-ΔRING; OBiO Technology), a C15/18A mutant
of TRIM22 (Flag-TRIM22-C15/18A; OBiO Technology),
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and an S32/S36A mutant of IκBα (srIκBα; OBiO Tech-
nology) were also used to infect cells.
After 48 h, infected cells were cultured in media con-
taining puromycin (2 μg/mL; Thermo Fisher Scientific) for
2 weeks to select for stable expression.
Subcellular fractionation
Nuclear and cytoplasmic fractions from LN229 and
U118MG were isolated using Nuclear and Cytoplasmic
Extraction Reagents (Thermo Fisher Scientific), according
to the manufacturer’s instructions. Subcellular distribution
of proteins was determined using western blot analysis.
GAPDH and Histone H3 served as loading controls for
cytosolic and nuclear fractions, respectively.
Real-time quantitative RT-PCR (qRT-PCR)
Total RNA was extracted from cells using TRIzol Reagent
(Thermo Fisher Scientific). RNA (2 µg) was reverse tran-
scribed into cDNA using the ReverTra Ace qPCR RT
Kit (Toyobo Life Science; Shanghai, China) according to the
manufacturer’s protocols. Quantitative PCR was performed
using the SYBR premix Ex Taq (Takara; Tokyo, Japan) on
the Real-Time PCR Detection System (480II, Roche; Basel,
Switzerland). GAPDH served as the internal control. Primers
used for PCR are listed in Supplementary Table S3.
Immunohistochemistry (IHC), immunofluorescence
(IF), and western blotting (WB)
IHC, IF, and WB were performed as previously described
[29]. The scoring system for TRIM22 IHC staining and all
antibodies used are described in Supplementary Materials
and Methods.
Co-immunoprecipitation (Co-IP)
Co-IPs were performed as previously described [29].
Briefly, cells were lysed in IP lysis buffer (Thermo Fisher
Scientific) containing a protease inhibitor cocktail (1%,
Sigma-Aldrich; St Louis, MO, USA). Total lysates (200 µg;
1 µg/µL) were incubated with primary antibodies (4 µL) or
IgG (4 µL) overnight at 4 °C with gentle shaking followed
by Protein A/G magnetic beads (Thermo Fisher Scientific)
for 2 h at room temperature. The immunoprecipitated
complexes were immunoblotted. The antibodies used are
listed in Supplementary Materials and Methods.
Cycloheximide (CHX) chase
LN229 and U87MG cells were infected with lentivirus
containing Cas9 and sgRNAs targeting TRIM22 (OBiO
Technology). LN229 and U118MG cells were infected with
lentivirus for ectopic expression of Flag-TRIM22-FL, Flag-
TRIM22-C15/18A, or Flag-TRIM22-ΔRING (OBiO
Technology). After selection, CHX (25 μg/mL; Apexbio;
Houston, TX, USA) was introduced to the culture medium
to inhibit translation, and cell lysates were prepared at the
indicated times. Protein (20 μg) was examined using wes-
tern blot analysis.
Cell number counting
Cells with target gene knockout or ectopic overexpression
(1 × 105/well) were seeded into six-well plates. Cells were
collected through trypsinization and counted every 24 h.
Cells were counted in three wells to obtain an average
count, and each experiment was performed in three inde-
pendent biological replicates.
Luciferase reporter assays
The NF-κB firefly-luciferase and renilla reporter constructs
(100 ng each, Promega; Madison, WI, USA) were co-
transfected into modified U87MG, U118MG, and LN229
cells using Lipofectamine 3000 (Thermo Fisher Scientific).
After 24 h, luciferase activities were examined using
the Dual-Luciferase Reporter Assay Kit (Promega).
Renilla activity was used to normalize luciferase reporter
activity. The promoterless firefly-luciferase vector
pGL4.15 served as the negative control (NC). Assays were
performed on cells in three wells for each experiment to
obtain an average count, and in three independent biological
replicates.
In vivo and in vitro ubiquitination assay
To assess in vivo ubiquitination, modified cells were treated
with 20 μM MG132 (Apexbio; Houston, TX, USA) for 6 h
before lysis, followed by co-IP and western blot analysis.
For in vitro ubiquitination assays, HA-IκBα proteins
purified from HEK293 cells were incubated with UBE1
(100 ng), UbcH5a (150 ng), human recombinant Ub (5 μg,
Boston Biochem; Cambridge, MA, USA) in the absence or
presence of Flag-TRIM22-FL or Flag-TRIM22-ΔRING
purified proteins with ubiquitination reaction buffer (Bos-
ton Biochem) at 30 °C for 90 min. Co-IPs were performed
on the incubation mixture using an anti-HA antibody fol-
lowed by western blot analysis using an anti-K48-linkage
specific polyubiquitin antibody.
Animal studies
Athymic nude mice (male, 4-week old; GemPharmatech
Co., Ltd; Nanjing, China) were randomly divided into five
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animals per group. Luciferase-expressing human glioma
cell lines (3 × 105 cells suspended in 10 μL PBS) were
implanted into the frontal lobes of nude mice using a ste-
reotactic apparatus (KDS310, KD Scientific; Holliston,
MA, USA). Tumor growth was examined at 6, 12, and
24 days after implantation using bioluminescence
imaging (IVIS spectrum in vivo imaging system, Perki-
nElmer; Hopkinton, MA, USA). Animals were euthanized
by cervical dislocation when they displayed any symptoms
of continuous discomfort, such as severe hunchback
posture, decreased activity, apathy, dragging legs, or more
than 20% weight loss. Mouse brains were harvested and
examined through hematoxylin and eosin and IHC/IF
staining.
Database (oncomine)
Oncomine (https://www.oncomine.org/) was used to com-
pare mRNA expression levels between GBM and non-
neoplastic tissue samples for TRIM5, TRIM21, TRIM22, and
TRIM38 in TCGA Brain datasets and TRIM56 in the Sun
Brain dataset.
Statistical analysis
All experiments were performed in at least three indepen-
dent biological replicates and reported as the mean ± the
standard error of the mean. The statistical significance was
calculated utilizing an unpaired two-tailed Student’s t test
for direct comparisons and ANOVA for multigroup com-
parisons. Survival curves were estimated using the
Kaplan–Meier method and compared using the log-rank
test. Correlation between TRIM22 expression levels and
clinicopathological factors was determined using the two-
tailed χ2 test or the Fisher’s exact test. Statistical analysis
was conducted using GraphPad Prism version 7.00 software
for Windows (GraphPad; La Jolla, CA, USA). Differences
were considered as statistically significant when P values
were < 0.05.
Results
Identification of TRIM22 as a positive regulator of
NF-κB signaling
To identify novel NF-κB signaling modulators, we screened
the activity of a panel of TRIM proteins using an NF-κB-
dependent transcriptional reporter containing five copies of
an NF-κB response element (NRE) located upstream of
luciferase. We chose to analyze five TRIM proteins,
TRIM5, TRIM21, TRIM22, TRIM38, and TRIM56, in our
luciferase assay based on two criteria. First, the expression
levels of the genes, based on molecular data in public
datasets in Oncomine, were significantly elevated in GBM
relative to NBT samples (Supplementary Fig. S1A). Sec-
ond, these five TRIM genes have not yet been reported to
have a role in the development of human gliomas. We
transfected siRNAs targeting each of these genes with the
luciferase reporter construct into U87MG and LN229 cells
and measured luciferase activity. TRIM22 siRNA decreased
reporter activity the most among the five TRIM genes in
both U87MG and LN229 cells compared with the NC group
(Fig. 1a). Using CRISPR/Cas9 technology, we knocked out
TRIM22 in both cell lines and found luciferase activity to be
significantly reduced (Supplementary Fig. S2A).
To elucidate the mechanism underlying reduced NF-κB
activity in TRIM22 knockout cells, we used western blot
analysis to examine total protein and phosphorylated levels
of core kinases involved in canonical NF-κB signaling.
Phosphorylated levels of the proteins that examined IKKα/β
(Ser176/180), IκBα (Ser32/36), and P65 (Ser536) were
uniformly decreased in TRIM22 knockout cell lines. How-
ever, total protein levels remained unchanged, except in the
case of IκBα, where they increased in response to TRIM22
knockout (Fig. 1b and Supplementary Fig. S3A).
To understand how loss of TRIM22 might contribute to
increased levels of IκBα protein, we first examined IκBα
mRNA levels. IκBα mRNA levels did not change sig-
nificantly with TRIM22 knockout in U87MG and LN229
cells (Fig. 1c). This result indicated that IκBα protein might
be stabilized in TRIM22 knockout cells. Therefore, we
determined the half-life of IκBα by treating modified
U87MG and LN229 cells with CHX. The half-life of IκBα
was prolonged by ~8 h in U87MG-sg-TRIM22 and LN229-
sg-TRIM22 cells compared to the sg-scramble groups
(Fig. 1d, e). Finally, K48-linked ubiquitination of IκBα in
control and modified U87MG and LN229 cells paralleled
TRIM22 expression; endogenous K48-linked ubiquitination
of IκBα was decreased with knockout of TRIM22 (Fig. 1f).
Taken together, these data suggested that deletion of
TRIM22 enhanced IκBα protein stability through loss of
proteasomal-mediated protein degradation.
TRIM22 deletion inhibits GBM cell proliferation
NF-κB signaling is considered to be a pivotal factor in indu-
cing genes that promote cell survival and proliferation [5]. Our
previous work also demonstrated a growth-promoting role for
NF-κB in GBMs [29]. To test whether TRIM22 is involved in
regulating GBM cell proliferation, growth curves were gen-
erated for TRIM22 knockout U87MG and LN229 cells and
compared to controls in vitro. Growth curves generated over
72 h revealed that TRIM22 knockout significantly attenuated
proliferation of U87MG and LN229 cells relative to control
cell lines (Fig. 2a). Reduced Ki-67 IF staining in knockdown
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cells further demonstrated that TRIM22 promoted GBM cell
proliferation in vitro (~50%; Fig. 2b).
We also examined tumor growth in vivo. Luciferase-
expressing modified and control cell lines were
Fig. 1 TRIM22 actives NF-κB signaling via K48-linked ubiquiti-
nation of IκBα. a Luciferase activity from U87MG and LN229 cells
transfected with siRNAs of TRIM5, TRIM21, TRIM22, TRIM38, or
TRIM56, along with a reporter plasmid carrying the NF-κB promoter
relative to negative control. b Western blot analysis to evaluate core
kinases in the NF-κB pathway in lysates (20 µg) prepared from
TRIM22 knockout cells. GAPDH was used as the loading control. c
qRT-PCR analysis of IκBα mRNA levels in modified U87MG and
LN229 cells relative to the control sg-scramble. GAPDH was used to
normalize samples. d Western blot analysis of IκBα protein in
TRIM22-depleted cells treated with cycloheximide (CHX; 25 μg/mL)
for 0, 8, 16, and 24 h. e Decay curve of IκBα levels normalized to
β-tubulin and to 0 h at the indicated time points from CHX experi-
ments. f Western blot analysis of IPs performed with antibody to IκBα
to detect endogenous IκBα ubiquitination from indicated cells. Anti-
body for K48-linked polyubiquitin was used on the western blot.
Student’s t test: n.s. not significant, *P < 0.05.
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orthotopically implanted in mice, and tumor growth was
monitored/quantified using bioluminescence. Tumors
derived from U87MG- and LN229-sg-TRIM22-1 or -2
cells were slower growing than the sg-scramble control
counterparts (Fig. 2c, d). Survival time of U87MG- and
LN229-sg-TRIM22-1 or -2 tumor-bearing animals was
also prolonged relative to controls (U87MG: 44 or
47 days vs. 29 days, sg-TRIM22-1 or -2 vs. sg-scramble,
respectively, P < 0.01; LN229: 52 or 52 days vs. 34 days,
sg-TRIM22-1 or -2 vs. sg-scramble, respectively, P <
0.01; Fig. 2e). IHC staining performed on sections from
xenografts showed that IκBα expression levels increased
in the absence of TRIM22, while Ki-67-IF staining was
decreased (Fig. 2f and Supplementary Fig. S4A, B).
Fig. 2 Knockout of TRIM22 inhibits proliferation of GBM in vitro
and in vivo. a Growth curves generated using cell counting over 72 h
for the cells indicated. b Representative images and quantification of
Ki-67 immunofluorescence staining from modified U87MG and
LN229 cells. c, d Images and quantification of in vivo biolumines-
cence imaging of U87MG- and LN229-NC and -sg-TRIM22-1 and -2
derived xenografts at the indicated time points. e Kaplan–Meier
survival analysis performed with survival data from indicated groups.
Log-rank test, P < 0.01. f Representative images of IHC staining for
TRIM22 and IκBα, and IF staining for Ki-67 levels in xenograft
sections from NC and sg-TRIM22-1 and -2 groups. Scale bars, 50 μm
for IHC, and 100 μm for Ki-67 IF staining. Student’s t test: n.s. not
significant, *P < 0.05, **P < 0.01.
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Collectively, these data indicated that TRIM22 promoted
growth of GBM tumors in vivo.
E3 ligase activity is required for TRIM22-mediated
GBM cell proliferation
TRIM22 is a RING domain E3 Ub ligase mediating protein
ubiquitination [31]. We therefore constructed two E3 ligase
defective TRIM22 mutants, one with a RING domain
deletion (TRIM22-ΔRING) and the other with the amino
acid changes at conserved cysteines C15 and C18 to ala-
nines (TRIM22-C15/18A) [32–34], to determine whether
the growth-promoting activity of TRIM22 is associated with
its E3 Ub ligase activity. Flag-tagged TRIM22-ΔRING,
TRIM22-C15/18A, TRIM22-full length (TRIM22-FL), and
empty vector (EV) were transfected into LN229 and
U118MG. Phosphorylated IKKα/β (Ser176/180), IκBα
(Ser32/36) and P65 (Ser536) were elevated, while total
IκBα was decreased, in cells overexpressing TRIM22
(TRIM22-FL) compared with EV groups (Fig. 3a and
Supplementary Fig. S5A). However, each of these proteins
remained unchanged in TRIM22-ΔRING/-C15/18A groups
compared with EV groups (Fig. 3a and Supplementary
Fig. S5A). TRIM22-FL also significantly increased cell
proliferation (Fig. 3b, c and Supplementary Fig. S5B). In
contrast, the RING domain deletion and C15/18A mutants
did not enhance cell proliferation over controls (Fig. 3b, c
and Supplementary Fig. S5B).
These data were confirmed in orthotopic xenograft mod-
els (Fig. 3d, e and Supplementary Fig. S5C, D). Survival
time of tumor-bearing mice was shorter in LN229- and
U118MG-TRIM22-FL groups (LN229: 26 vs. 39 days,
TRIM22-FL vs. EV, respectively, P < 0.05; U118MG: 27 vs.
34 days, TRIM22-FL vs. EV, respectively, P < 0.05; Fig. 3f),
but remained stable in LN229- and U118MG-TRIM22-
ΔRING (LN229: 39 vs. 39 days, TRIM22-ΔRING vs.
EV, respectively, P= n.s.; U118MG: 35 vs. 34 days,
TRIM22-ΔRING vs. EV, respectively, P= n.s.; Fig. 3f)
relative to EV groups. Taken together, these data suggested
that the TRIM22 plays an important role in driving tumor
growth possibly through its E3 Ub ligase activity.
TRIM22 ubiquitinates IκBα
To explore whether the E3 ligase activity is critical for
TRIM22-mediated activation of NF-κB signaling, we tested
TRIM22-ΔRING and TRIM22-C15/18A in NF-κB luci-
ferase reporter assays compared with TRIM22-FL and EV
groups. NF-κB signaling activity increased significantly in
LN229 and U118MG cells transfected with TRIM22-FL,
but remained unchanged in cells expressing TRIM22-
ΔRING/-C15/18A (Fig. 4a and Supplementary Fig. S5E).
Elevated nuclear accumulation of P65 in LN229- and
U118MG-TRIM22-FL groups was the further demonstra-
tion of an enhanced activation of NF-κB signaling, but
remained unchanged in cells expressing TRIM22-ΔRING/-
C15/18A (Fig. 4b and Supplementary Fig. S5F). In CHX
studies, the half-life of IκBα was decreased by ~4 h in
LN229-TRIM22-FL cells and ~8 h in LN229-TRIM22-FL
cells compared to EV groups, while changes in LN229- and
U118MG-TRIM22-ΔRING/-C15/18A were not significant
(Fig. 4c, d and Supplementary Fig. S5G, H). Furthermore,
both in vitro and in vivo, TRIM22-FL overexpression
induced endogenous K48-linked ubiquitination of IκBα,
while the RING domain deletion and C15/18A mutants had
no effect (Fig. 4e, f and Supplementary Fig. S5I).
To test whether TRIM22 directly binds to IκBα, we
performed co-IPs using lysates prepared from HEK293
transiently transfected with Flag-tagged TRIM22 and
HA-tagged IκBα expression vectors. Immunoprecipita-
tion with anti-FLAG or anti-HA antibodies brought down
both Flag-tagged TRIM22 and HA-tagged IκBα indicat-
ing that the two tagged proteins were associated with each
other in HEK293 cells (Fig. 4g). An endogenous physical
interaction between the two proteins was confirmed in co-
IPs using U87MG, LN229, and U118MG cell lysates
(Fig. 4h). To investigate the functional domains respon-
sible for their interaction, a series of deletion mutant
constructs for TRIM22 and IκBα were expressed in cells,
and co-IPs were performed. AR4 and AR5 domains in
IκBα, or amino acids 182–317, brought down TRIM22.
In TRIM22, amino acids 89–131 (B-Box domain),
133–223 (coiled-coil domain), and 352–498 (SPRY
domain) were necessary to bring down IκBα (Fig. 4i, j).
Interestingly, although the TRIM22 ring domain mutant
was less efficient at binding IκBα, the domain was not
essential for the two proteins to interact. Thus, TRIM22
might promote the development of human glioma by
facilitating proteasomal-mediated degradation of IκBα, a
negative regulator of NF-κB signaling.
TRIM22 promotes K63-linked ubiquitination of IKKγ
Loss of TRIM22 also led to decreased phosphorylation of
IKKα/β (Ser176/180), IκBα (Ser32/36), and P65, indicating
that it may have some role in the phosphorylation and thus
activation of these proteins, which are mediators of so-called
canonical NF-κB signaling (Fig. 1b). We therefore per-
formed co-IP assays with anti-TRIM22 antibodies to deter-
mine whether any of these proteins were associated with
TRIM22 in GBM cell lines. We found that IKKγ, rather than
IKKα/β, was associated with TRIM22 in GBM cells
(Fig. 5a). We furthermore found that K63 ubiquitination
levels of IKKγ paralleled TRIM22 protein levels (Fig. 5b). In
summary, these data suggested that TRIM22 might regulate
NF-κB activation through activation of the IKK complex.
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IκBα mediates the tumor growth-promoting effects
of TRIM22
To determine whether TRIM22 activates NF-κB signaling
through IκBα, we introduced a construct expressing an IκBα
phosphorylation mutant (S32/36A; srIκBα) into LN229 and
U118MG cells. The substitution of S32 and S36 with alanine
leads to a constitutively unphosphorylated state in srIκBα,
which prevents its degradation and subsequent NF-κB acti-
vation [35]. Thus, we first tested whether TRIM22 induced
Fig. 3 Overexpression of TRIM22 promotes proliferation of GBM
in vitro and in vivo via its RING domain. a Western blot analysis to
evaluate components of the NF-κB pathway in lysates prepared from
LN229- and U118MG-EV, TRIM22-FL and TRIM22-ΔRING cell
populations. GAPDH was used as the loading control. b Growth
curves generated using cell counting and c Ki-67 immunofluorescence
staining for transfected cells in a. Scale bars, 100 μm. d, e
Representative images and quantification of in vivo luciferase biolu-
minescence from indicated cells orthotopically implanted into the
brains of nude mice at day 6, 12, and 24 after injection.
f Kaplan–Meier analysis of survival for tumor-bearing mice implanted
with indicated cells. Log-rank test, P < 0.05. Student’s t test: n.s. not
significant, *P < 0.05, **P < 0.01.
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NF-κB activity in the presence of srIκBα in glioma cells,
using the NF-κB luciferase reporter construct. In LN229- and
U118MG-TRIM22-FL cells, NF-κB transcriptional activity
was increased relative to controls (~2×; Fig. 6a). However,
NF-κB activity did not increase in TRIM22 overexpressing
cells in the presence of srIκBα (Fig. 6a).
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In cell number counting assays, srIκBα blocked the
increase in cell proliferation mediated by overexpression of
TRIM22 in LN229 and U118MG cells relative to controls
(Fig. 6b). The growth-promoting properties of TRIM22 were
also shown to be mediated by IκBα in an orthotopic tumor
model. LN229- and U118MG-TRIM22-FL tumors were
greater in size compared with EV groups, but this effect was
abolished by srIκBα overexpression (Fig. 6c, d). Overall
survival was also correspondingly reduced in mice bearing
LN229- and U118MG-TRIM22-FL tumors relative to control
mice (LN229: 27 vs. 35 days, TRIM22-FL vs. EV, respec-
tively, P < 0.05; U118MG: 29 vs. 39 days, TRIM22-FL vs
EV, respectively, P < 0.05; Fig. 6e). However, srIκBα over-
expression in the context of TRIM22 overexpression brought
overall survival back to nearly control group levels (LN229:
35 vs. 39 days, TRIM22-FL+ srIκBα vs. EV, respectively,
P= n.s.; U118MG: 35 vs. 35 days, TRIM22-FL+ srIκBα vs.
EV, respectively, P= n.s.; Fig. 6e). These results indicated
that IκBα is a key effector in TRIM22-promoted growth of
GBM cell populations in vitro and in vivo.
TRIM22 predicts higher grade of human glioma
malignancy
To characterize its role in the progression of human glio-
mas, we evaluated TRIM22 protein levels in a cohort of
primary gliomas on a tissue microarray and NBT samples
using IHC. The histology and distribution of the samples
was as follows: WHO grade II (n= 30), WHO grade III
(n= 31), WHO grade IV (n= 51, GBMs), and non-
neoplastic brain (NBT, n= 10). TRIM22 was preferentially
expressed in high grade gliomas (n= 82; HGG, WHO
grade III-IV) compared with low grade gliomas (n= 30;
LGG, WHO grade II; P < 0.001; Fig. 7a, b and Supple-
mentary Table S4). Expression in NBT samples was nearly
absent (Fig. 7a, b and Supplementary Fig. S6A). WB of
lysates prepared from primary tumors (n= 12; WHO grades
II–IV) and NBT samples (n= 3) confirmed the over-
expression of TRIM22 in human gliomas (Fig. 7c). Finally,
increased expression of TRIM22 correlated with other fea-
tures of more aggressive gliomas, including wild-type IDH1
(P < 0.001) and wild-type ATRX (P= 0.0054).
We also performed experiments with GBM#P3 and
GSC#BG5 cells, which more faithfully retain the genetic
features of the matching primary GBM [36]. Knockout of
TRIM22 in GBM#P3 cells led to decreased tumor
growth in vivo (Fig. 7d, e) and prolonged the survival time
of tumor-bearing mice (GBM#P3: 44 or 47 days vs.
34 days, sg-TRIM22-1 or -2 vs. sg-scramble, respectively,
P < 0.05; BG5: 55 or 52 days vs. 35 days, sg-TRIM22-1 or -
2 vs. sg-scramble, respectively, P < 0.05; Fig. 7f). These-
data are in agreement with a growth-promoting role for
TRIM22 in the development of human gliomas.
Discussion
Targeting NF-κB signaling is emerging as a promising
therapeutic strategy for GBM. To date, studies regarding
NF-κB as a potential therapeutic target have focused on
Fig. 5 TRIM22 promotes K63-linked ubiquitination of IKKγ. a
Western blot analysis of co-IPs to demonstrate association of TRIM22
with IKKα/β or IKKγ in U87MG, LN229, and U118MG cells.
b Western blot analysis for IKKγ of co-IPs with K63-linkage specific
polyubiquitin antibody in the indicated modified U87MG, LN229, and
U118MG cells.
Fig. 4 TRIM22 ubiquitinates IκBα. a Luciferase activity for NF-κB
luciferase or control reporter constructs in modified LN229 and
U118MG cells. b Western blot analysis of cytoplasmic (Cyto) and
nuclear (Nuc) fractions prepared from indicated cells. Immuno-
fluorescence for P65 in modified LN229 and U118MG cells showing
cellular localization. Scale bars, 20 μm. c Western blot to detect IκBα
levels after 0, 4, 8, and 12 h of cycloheximide (CHX; 25 μg/mL)
treatment in modified LN229 and U118MG cells compared with
controls. d Line graph showing IκBα protein levels normalized to β-
tubulin and to 0 h at the indicated time points. e Western blot of IP of
IκBα incubated with anti-K48-linkage specific polyubiquitin antibody
to detect ubiquitination of IκBα in an in vitro assay. f In vivo ubi-
quitination assay of IκBα. g Western blot analysis of co-IPs performed
on lysates prepared from HEK293 cells transfected with Flag-TRIM22
and HA-IκBα. h Western blot analysis of co-IPs performed using anti-
IκBα or -TRIM22 antibody on lysates prepared from U87MG, LN229,
and U118MG cells. i Schematic representation of wild-type IκBα and
the indicated deletion mutants. Western blot analysis of co-IPs per-
formed on lysates prepared from HEK293 cells transfected with Flag-
TRIM22 alone or together with indicated HA-IκBα constructs. Upper
panels represent co-IPs performed with anti-HA; lower panels repre-
sent input protein. j Schematic representation of wild-type TRIM22
and the indicated deletion mutants. Western blot analysis of co-IPs
performed on lysates prepared from HEK293 cells transfected with
HA-IκBα alone or together with indicated Flag-TRIM22 constructs.
Student’s t test: n.s. not significant, *P < 0.05, **P < 0.01.
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nonspecific compounds or inhibitors of IKK, which impact
many of the pathways central to the malignant phenotype of
GBM [37]. However, NF-κB inhibitors initiate a broad range
of responses and side effects. Thus, glioma patients may
benefit from inhibition of specific factors upstream of var-
ious mediators of NF-κB signaling [38]. In this study, we
identified TRIM22 as a potential modulator of NF-κB sig-
naling, by screening activity from an NF-κB-dependent
transcriptional luciferase reporter construct in response to
knockout of five TRIM genes overexpressed in GBM. We
demonstrated that TRIM22 promotes glioma cell prolifera-
tion in vitro and tumor formation in vivo, and that these
properties are linked to its intrinsic E3 Ub ligase activity.
TRIM22 aids in the generation of K48-linked Ub conjugates
of IκBα, a key negative regulator of NF-κB signaling, and
thus promotes enhanced proteasomal-mediated degradation
of the protein. TRIM22 also associates and generates K63-
linked Ub conjugates of IKKγ, which in turn activate IKK
complexes and subsequently degrade IκBα (model in
Fig. 7g). TRIM22 exhibited increased expression in primary
human GBM specimens, and high TRIM22 correlated with
factors associated with higher grade gliomas. Our study
therefore revealed a novel regulatory mechanism for IκBα
degradation and NF-κB activation, and a critical role for
TRIM22 in glioma tumorigenesis.
TRIM22 was first identified as an IFN-induced protein
and also found to be a transcriptional target gene of TP53
[39, 40]. Although the proximal promoter of TRIM22 is not
Fig. 6 TRIM22 promotes the growth of GBM via IκBα. a Luci-
ferase activity in modified LN229 and U118MG cells transfected with
NF-κB luciferase reporter constructs. b Growth curves generated with
cell counting performed over 72 h. c, d In vivo bioluminescence
imaging and quantification of modified LN229 and U118MG cells
derived xenografts at the indicated time points. e Kaplan–Meier sur-
vival analysis performed with survival data of tumor-bearing animals
implanted with the indicated cells. Log-rank test, P= n.s., P < 0.05.
Student’s t test: n.s. not significant, *P < 0.05, **P < 0.01.
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p53-responsive, a functional enhancer-like element was
found in intron 1 of the TRIM22 gene. TP53, which is
frequently deregulated in GBM, plays a central role in the
classification of GBM molecular subtypes and GBM pro-
gression [41]. We found that TRIM22 is preferentially
expressed in U87MG and A172 cell lines (P53 wild type)
compared with LN229 and U118MG cell lines (P53
mutated; data not shown here). The significance of the
association between TRIM22 and P53 status in human
glioma requires further investigation.
TRIM22 contains a conserved RING domain, which
suggests that it has a potential role as an E3 Ub ligase
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involved in posttranscriptional modification of certain pro-
teins [31, 32, 42]. Specificity of the Ub conjugation system
is derived from the direct association of the E3 ligase with
its substrates. Here, we demonstrated that TRIM22 inter-
acted with both IκBα and IKKγ, causing ubiquitination
which was E3 ligase activity-dependent. Overexpression of
TRIM22, which promoted glioma cell proliferation in vivo
and in vitro, was blocked through deletion of the RING
domain or substitution of two conserved cysteine sites by
alanine. Thus, we determined that the E3 ligase activity of
TRIM22 was required for its function. However, it has been
reported that the C terminal SPRY domain [27, 32, 43],
which is in a region that we found to be necessary for the
interaction between TRIM22 and IκBα, is also important for
TRIM22-mediated biological functions. Therefore, further
study is necessary to determine which region of TRIM22
might be relevant to the development of human gliomas.
IKKγ, also known as the NF-κB essential modulator, is a
regulatory subunit of the IκB kinase complex and has a
critical role in the activation of NF-κB [44]. IκBα binds
strongly to NF-κB and sequesters it in the cytoplasm in
resting cells. Upon stimulation, the IκB kinase/IKK com-
plex phosphorylates IκBα at serine 32/36. NF-κB becomes
active as phosphorylated IκBα is released, and undergoes
K48-linked polyubiquitination and proteasome-dependent
degradation [37]. Previous studies have demonstrated that
the F-box protein β-TrCP1 is involved in the proteasomal-
mediated degradation of IκBα [45]. However, a subsequent
study showed that IκBα was still degraded when β-TrCP1
was knocked out, suggesting that other E3 ligases might
target IκBα for proteasomal-mediated degradation [45].
Therefore, we screened the activity of a panel of TRIM
proteins using the NF-κB response reporter, which led to
the identification of TRIM22 as a potential regulator of NF-
κB signaling. We demonstrated that TRIM22-targeted IκBα
for proteasomal-mediated degradation and further enhanced
this protein degradation by modifying K63-linked poly-
ubiquitin chains on IKKγ, despite the existence of linear
and K27-linked ubiquitination of IKKγ [46, 47].
In summary, our study revealed a novel regulatory
mechanism of NF-κB activation, in which TRIM22, an E3
ligase, promotes K48- and K63-linked ubiquitination of
IκBα and IKKγ, respectively. TRIM22 induced NF-κB
signaling in GBM, which drives tumor growth and pro-
gression. Finally, our study defines TRIM22 as a candidate
therapeutic target. Pharmaceutical inhibition of its E3 ligase
activity or the interaction between these three proteins may
provide a promising strategy for the treatment of GBM.
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